Gonadotropin-releasing hormone antagonists in prostate cancer

Adam S. Kittai, Jessica Blank, Julie Graff

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Androgen deprivation therapy (ADT) comes in several forms, such as surgical castration or medical castration using gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist therapy. ADT is a critical treatment for high-risk and metastatic prostate cancer. There are important differences between GnRH agonists and antagonists. Here we review the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix. We also comment on the potential risks and benefits of degarelix, particularly when it comes to cardiovascular health. Finally, we describe an oral GnRH antagonist, which is not currently used in prostate cancer, but is included for completeness.

Original languageEnglish (US)
Pages (from-to)599-606
Number of pages8
JournalONCOLOGY (United States)
Volume32
Issue number12
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Gonadotropin-releasing hormone antagonists in prostate cancer'. Together they form a unique fingerprint.

  • Cite this